Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 30, 2011

View Archived Issues

U.S. study describes new radiosensitizer's mode of action

New suicide gene strategy shows promise as safety switch for cell therapy

PMI inhibitor improves N-glycosylation in model of glycolytic disorders

Combination therapy for radiation sickness shows promise in mice

Phase III BTOG2 trial assesses combination therapies for advanced lung cancer

Dengue virus vaccine assessed in healthy volunteers

Study evaluates repeated daily oxytocin as a therapy for anxiety

New peptides with anxiolytic activity designed in Japan

Avidin discloses novel matrix metalloproteinase inhibitors

Emergent BioSolutions advances TRU-016 into phase II for leukemia indication

Merck & Co. patents new soluble guanylate cyclase activators

Toray, Japan Tobacco and Torii terminate joint development of TRK-820

Prima Biomed provides update on oral cervical cancer vaccine program

Recruitment begins in phase II SyB L-0501 trial in Japan

Axelar advances phase II AXL-1717 trial in lung cancer

Collaborating Japanese companies present new antioxidants

Novel MOMP-based products claimed at University of Surrey

RegeneRx aims to close licensing deal for ophthalmic drug candidate

FDA approves test to detect Staphylococcus infection

Gilead Sciences synthesizes novel compounds for hepatitis C

New Quidel assay approved for U.S. market

Cynapsus Therapeutics secures funds to develop sublingual Parkinson's disease drug

Alexion Pharmaceuticals announces planned acquistion

University of Colorado prepares new histone deacetylase inhibitors

Peregrine provides update on phase II bavituximab trial in hepatitis

Janssen submits supplemental NDA for Xarelto

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.